Appeal No. 2002-1358
Application No. 09/467,903
pharmaceutical composition comprising antibody fragments. Thus, the present claims
have been limited by Appellants to a pharmaceutical composition comprising antibody
fragments.
Technical Background
The claimed invention encompasses a pharmaceutical composition comprising a
therapeutically effective amount of a monoclonal antibody fragment bound to the
surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells and a
pharmaceutically acceptable carrier. The monoclonal antibody fragment is specifically
defined in the claims with reference to particular variable regions of the heavy and light
chains of the antibody fragments. Specification, pages 4, 7-8. Anticancer agents
encapsulated in the liposome include carcinostatic agents such as adriamycin,
daunomycin, mitomycin, cisplatin, vincristine, toxins such as ricin A and diphtheria toxin,
and antisense RNA. Specification, page 11. The antibody portion of the
pharmaceutical composition is provided to target and concentrate an anticancer agent
to a tissue or organ to be treated. Specification, pages 1 and 41.
The preparation and use of Fab’ fragments bound to liposome are disclosed in
the specification at pages 11-12. The Fab’ fragments are prepared from F(ab')2
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007